Click Therapeutics Underscores Its Commitment to Innovation and Leadership in Software as Prescription Medical Treatments with Launch of New Brand Identity

Click Therapeutics, Inc. (“Click”), a leader in prescription medical treatments as both prescription digital therapeutics and software-enhanced drug™ therapies, has launched an updated brand identity and new website to reflect the company’s evolution and vision for the future of medicine. This brand update follows a year of significant successes for Click including the FDA clearance of the first prescription digital therapeutic for the adjunctive treatment of major depressive disorder symptoms, the successful outcome of the CT-132 pivotal study for the preventive treatment of episodic migraine, the launch of a new product offering, Click SE™, and a completed Series C financing, with the investment round led by Dassault Systèmes and Medidata.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250402820814/en/

Click’s updated branding celebrates its role as a forward-thinking innovator in the digital therapeutics industry and its emphasis on personalization, cutting-edge technology, and a science-led approach. Inspired by the value created at the intersection of two disciplines - medicine and technology - this refreshed brand identity highlights Click’s multidisciplinary approach, which combines clinical science with the power of software to create digital therapeutics that can bridge gaps in care for patients and improve clinical outcomes.

“Click Therapeutics has rapidly grown over the last few years, making significant strides in the development of digital therapeutics and software-enhanced drug therapies, and producing robust clinical data that demonstrates how these solutions can improve patient outcomes,” said David Benshoof Klein, Founder and Chief Executive Officer at Click Therapeutics. “It’s important that our brand reflects who Click Therapeutics is today and our vision to enhance the standard of care for patients with unmet medical needs.”

Click’s leadership team worked to develop a brand architecture and visual identity that embodies Click’s personalized and innovative treatment offerings while emphasizing the company’s unwavering commitment to patients. This carries through to the features of the new website, which was created with patient accessibility in mind, and improves access to publications and information explaining Click Therapeutics’ products and research. In addition, the updated brand is designed to speak to the unique value that can be created when bringing together traditionally distinct areas of expertise, as captured by use of the moiré effect.

“Our updated brand embodies our vision to seek out new and exciting ways to deliver added benefits to patients, physicians, pharma, and the healthcare ecosystem,” said Austin Speier, Click’s Chief Strategy Officer, who led the rebranding initiative. “The new website also highlights our expansion into software-enhanced drug therapies, which directly build upon our record of success in digital therapeutics, and offers a platform for us to communicate our insights and expertise in areas such as artificial intelligence and patient-centric design.”

The new website prominently features software-enhanced drug™ therapies, part of a new product offering called Click SE™. The Click SE™ offering combines Click’s patent-protected and clinically validated digital therapeutic technology with pharmacotherapy to create software-enhanced drug™ treatments in collaboration with pharmaceutical companies. These innovative combination therapies are designed to target the unique needs of a specific medication and patient population to deliver added clinical benefit compared to medication alone.

The company was supported by and wishes to acknowledge the international award-winning creative agency, Base Design, in developing the updated brand and new website. Brussels Digital Director, Thomas Byttebier shared, "Click Therapeutics is this rare blend of deep science and cutting-edge tech, and we wanted their website to feel the same way. It had to be precise and credible, but also sleek and intuitive, something that reflects how they’re shaping the future of digital medicine."

This brand refresh comes on the heels of Click's Series C funding round, announced by strategic investor Dassault Systèmes earlier this month. As part of this investment, Click will closely partner with Medidata, a Dassault Systèmes brand, and work collectively to leverage their global presence and expertise to support the development of new therapies, including Medidata’s over 8,000 active annual studies and approximately 2,300 life sciences customers, to better enhance the healthcare experience for patients.

The transaction also strengthens the existing relationship between Medidata and Click. The continued relationship and subsequent investment will empower the companies to set a gold standard and unified offering for digital-plus-drug clinical trial design and execution, and provide a clear path to best-in-class prescription digital therapeutic and software-enhanced drug™ product approvals for therapeutic innovators worldwide.

About Click Therapeutics

Click Therapeutics, Inc. develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. We are expanding the possibilities of medicine with Digital Therapeutics™ that combine clinical science with the power of software to create a new way to treat disease.

Operating at the intersection of biology and technology, we use a proprietary platform-based approach to therapeutic development that leverages patient-centric design principles and innovative AI-based technologies to deliver a unique combination of engagement and clinical outcomes, consistently. Digital therapeutics on Click’s platform are regulated, clinically validated prescription mobile applications that can address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.

Click Therapeutics, in collaboration with Otsuka, developed the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms, Rejoyn™. In October 2024, in response to FDA guidance on prescription drug use-related software (PDURS), we launched Click SE™ to extend our digital therapeutics platform and expertise to the development of software-enhanced drug™ therapies that combine software with pharmacotherapy to offer added clinically meaningful benefit to patients.

Our commitment to advancing digital medicine means we continually improve our platform technologies, ensuring we stay at the forefront of cognitive, behavioral, and neuromodulatory therapeutic innovation, to achieve the best possible outcomes for patients. Our diverse team of innovators—spanning clinicians, researchers, technologists, designers and more—works together to create cutting-edge digital therapeutics, united in the mission to transform patient care. For more information, visit www.clicktherapeutics.com and connect with us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250402820814/en/